HTG2014-Section-Header-publications

Categories

Filter by Topics

1L therapy; bispecific antibodies 478P TA-ness ABC- type ADCC Gene Alteration adolescents AI alcohol consumption ALK alzheimer's Angiogenesis Anti-TNF Alpha Therapy antibody drug conjugates antiEGFR apoptosis Apoptosis Asthma Autocrine Signaling Autoimmune Disorder Avelumab B Cells BCL2A1 BCL6 benign Biofluid Biology of neoplasia biomarker Biomarker Biomarker Analysis Biomarker Discovery Biomarker Validation biomarkers Biomarkers Bladder Bladder cancer Bladder Cancer Blastic plasmacytoid dandritic cell neoplasm BPDCN blindness Blood Brain Breast Cancer Breast milk Burkitt lymphoma cancer genetics Cancer Genomics CAR-T-cells Cardiovascular Disease Castleman Disease CD10 CD3 CD8 CDKN1A CDKN2A mutation Cell Free Plasma Cells Cerebrospinal Fluid Cetuximab Chemokines Childhood Atopic Dermatitis chronic kidney disease Chronic Obstructive Pulmonary Disease Circulating miRNAs circulating tumor Circulating tumor cells classifications cMET cognition Colon Colon cancer Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy cornea COVID-19 cultivated limbal epithelial cells Clec Custom mRNA cyclic AMP‑dependent transcription factor ATF‑4 Cytokine Cytokines Cytotoxic T Cells cytotoxicity dementia Dementia Developmental Immunotherapy Developmental Therapeutics Diabetes diabetic nephropathy Differential Expression Differential Gene Expression Analysis Diffuse Large B-Cell Lymphoma diffuse large B-cell lymphoma DLBCL DLBCL COO DNA damage‑inducible transcript 3 protein DNA lymphoma Drug Response Drug Safety Drug Targets Drug-induced Liver Injury ear Efficacy EGFR Muatations EMT Encephalophy end stage kidney disease Endothelial cell epidemiology epidermal growth factor receptor EGFRHER epigenomics Epstein-Barr ERBB3 Esophageal Cancer Exosomes extracellular miRNAs Extracellular Vesicles extraction-free RNA workflow Fabry Disease Feasibility FFPE FGF Ligand Trap FGFR Fibrous Tumors FOLFOX7 Follicular lymphoma GEIS gene expression Gene Expression gene expression profiling Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors HCC Head and neck cancer Head and Neck Cancer Heart hepatocellular carcinoma HER-2 HER2 HER2- Histone Deacetylase Inhibitors HLA-E Homing HPV HR+ HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBCL Cell of Origin Panel HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq miRNA WTA HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay HTP ibrutinib Ibrutinib Immune Cells Immune Checkpoint Inhibitors Immune microenvironment Immune Related Genes Immune Response Immune System Immune Tolerance Immune-related Colitis Immuno-Oncology immuno-oncology agents immunohistochemistry IHC Immunologically hot tumours IMMUNOSARC Immunotherapy immunotherapy Inflammation Integrins inverted papilloma IRF4 ISG JAVELINE bladder Juvenile Arthritis Kidney kikuchi-fujimoto disease KRAS Kruppel-like factor 5 Limb ischemia limbal stem cell deficiency LSCD Liposarcoma Liquid Biopsy Liver liver disease liver tissue Lung Lung cancer Lupus Lymph Node Metastasis lymphatic Lymphocytes Lymphoid Neoplasia lymphoma Lymphoma lymphomas machine learning Machine Learning malignancy sinonasal malignant mCRC Mechanism of Action Melanoma Mesothelioma MET metastatic colorectal cancer CRC Method Comparison Microenvironment microRNA MicroRNA miR-122-5p miR-3937 miRNA miRNA WTA miRNA-375 Molecular Characterization Mouse Mouse mRNA mRNA mRNA custom mTOR pathway mTOR signaling multi-omics Multiple Myeloma multiple myeloma MUM1 Muscle mutation analysis Mutations MYC NAFLD Nash and Fibrosis native African men Natural Killer Cells Neoantigens Neuroendocrine Tumor Neurologic nivolumab NKG2A Non-alcoholic fatty liver disease non-Hodgkin Lymphoma Non-small cell lung cancer Novel Therapeutic Targets NTRK1 nuclease protection assay obesity OBP Oesophageal Adenocarcinoma Oncology Oncology-Biomarker OPSCC Oral Cancer Oral Squamous Cell Carcinoma Oropharyngeal Cancer Osteoarthritis Osteoclast Ovarian cancer PALLET PALOMA-2 Pan-Cancer PanB Pancreas Pancreatic Cancer Paralysis Parkinson's Disease Pathogenesis pathophysiology Pathway analysis Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-1 PD-L1 PENELOPE-B PFAS PIK3CA mutation PIP Placenta placenta Plasma Plasma miRNAs Platform Comparison PMAIP1 population based Precision medicine predictive biology Predictive Biomarkers Predictive Modeling Programmed cell death protein 1 Progression free-survival progression of renal failure Prostate Prostate Cancer prostate cancer prostate genomics Protein Protein Interaction network qNPA qPCR race disparities Radioimmunotherapy RAS Rearrangements Refractory DLBCL Relapsed DLBCL Renal Cell Carcinoma Renal Disease Reproductive Response rate RET Reveal Rheumatoid Arthritis Risk Score ROS1 safety sarcoma Sarcoma Sequencing Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures single cell Sinonasal Carcinoma Skin soft tissue sarcoma SPECS Lung Consortium squamous cell carcinoma Squamous cell carcinoma STAT6 pathway Sub-typing surface plasmon Surveillance Survival Outcomes Survival plots Synovial Fluid Synovial Sarcoma synthetic miRNA T-Cell T-cells targeted therapeutics Technology Comparison Testicular cancer Therapeutic Response Therapeutic targets Thymic Carcinoma Thyroid Cancer tislelizumab TMB tomentosin Toxicity TP53 mutation Transcriptome transcriptome profiling Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes Tumor Microenvironment tumor microenvironment Urine Urothelial carcinoma Uterus VEGFR vestibular schwannoma VS Wound healing Xenograft Tissue Zanubrutinib

2022

2021

Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib

Balasubramanian, S., et al., Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib, British Journal of Haematology,  https://doi.org/10.1111/bjh.17450

View External Link

Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure

Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure. Poster presentation presented at: 16th International Conference on Malignant Lymphoma (ICML) Lugano. June 18-22, 2021

Download pdf 3.4MB

2020

Acalbrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase lb/ll Single Arm Study

Davies, A., et al. Acalbrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase lb/ll Single Arm Study. Blood Journal 2020 NOV 5 136 (S1):88-89.

View External Link

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine

Lodhi, N., et al. Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. Oncotarget 2020(11):44, 4055-4073. 

Download pdf 3.6MB

2019

Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with baseline Metabolic Tumor volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial.

Richter, J., et al. Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Blood Cancer Journal 2019 Aug 19; 9(67).

Download pdf 757KB

The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination

Tarantelli, C., et al. The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination. Paper presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; 2019 Jun 18-22; Lugano, Switzerland.  Hematological Oncology VOL 37, Issue S2. https://doi.org/10.1002/hon.90_2629

View External Link

Page last updated October 27, 2022